The SARS-CoV-2 virus is continuously evolving and structural changes to the virus may impact the efficacy of antibody therapies and vaccines. A study published February 17 in PLOS Pathogens by Anshumali Mittal at the University of Pittsburgh and colleagues describes the structural and functional landscape of neutralizing antibodies against the SARS-CoV-2 spike protein and discuss the effects of mutations on the virus spike protein that may allow it to evade antibody responses.
Mutations in SARS-CoV-2 spike protein receptor-binding domains may yield new vaccine-resistant variants
The SARS-CoV-2 virus is continuously evolving and structural changes to the virus may impact the efficacy of antibody therapies and vaccines. A study published February 17 in PLOS Pathogens by Anshumali Mittal at the University of Pittsburgh and colleagues describes the structural and functional landscape of neutralizing antibodies against the SARS-CoV-2 spike protein and discuss the effects of mutations on the virus spike protein that may allow it to evade antibody responses.